Press releases

ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference

ORYZON to give updates on corporate progress in November

ORYZON reports results and corporate update for quarter ended September 30, 2022

ORYZON to give updates on corporate progress in October

ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

ORYZON to give updates on corporate progress in September

ORYZON collaborates with the CMT Research Foundation in the US

ORYZON reports results and corporate update for half-year ending June 30, 2022

ORYZON enters cooperative research and development agreement (CRADA) with U.S. National Cancer Institute to develop iadademstat in different cancers

ORYZON announces a New Financing through a Convertible Bond Program for a Total amount up to €20 Million over 30 months